DEVELOPMENT OF AN ANTIGEN CAPTURE ASSAY FOR HTLV-I

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$49,891.00
Award Year:
1989
Program:
SBIR
Phase:
Phase I
Contract:
N/A
Agency Tracking Number:
11101
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Biotech Research Laboratories
1600 E Gude Dr, Rockville, MD, 20850
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
N/A
Principal Investigator
 () -
Business Contact
Phone: () -
Research Institution
N/A
Abstract
PHASE I RESEARCH IILL DEVELOP A PROTOTYPE ELISA ANTIGEN-CAPTURE KIT TO MEASURE HTLV-I CORE PROTEINS P19 AND P24 PRODUCED DURING VIRUS REPLICATION IN CELLS. HTLV-I IS LINKED TO THE DEVELOPMENT OF ADULT T-CELL LEUKEMIA AND TOTROPICAL SPASTIC PARAPARESIS, A NEUROLOGICAL DISEASE OF INTEREST TO RESEARCHERS ON MULTIPLE SCLEROSIS. TRACKING THE PROGRESS OF HTLV-I INFECTION IN TISSUE CULTURES IS MORE DIFFICULT THAN TRACKING HIV INFECTION: HTLV-I SELDOM KILLS THE CELLS IT INFECTS, AND THE REVERSE TRANSCRIPTASE (RT) IT PRODUCES IS NOT VERY ACTIVE IN CURRENT RT ASSAYS. THEREFORE, A COMMERCIAL KIT THAT MEASURES THE CORE PROTEINS PRODUCED DURING INFECTION WILL BEVALUABLE IN STUDIES OF HTLV-I IN TISSUE CULTURE. THE PROTOTYPE ASSAY WILL USE P19 AND P24 ANTIBODIES AS CAPTURE ANTIBODIES. HIGH-TITER HUMAN SERA WILL BE USED AS THE DETECTOR ANTIBODY UNTIL HYPERIMMUNE RABBIT SERA IS AVAILABLE. THE PROTOTYPE ASSAY WILL BE MORE SENSITIVE THAN RT ASSAYS IN TRACKING HTLV-I INFECTION, BUT ITS SENSITIVITY WILL BE LIMITED BY THE CURRENT LACK OF VERY HIGH-AFFINITY MONOCLONAL ANTIBODIES FOR P19 AND P24. PRODUCTION OF HIGH-AFFINITY MONOCLONAL ANTIBODIES WILL BEGIN IN PHASE I.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government